7,574 results match your criteria Thyroid Medullary Carcinoma


Medullary thyroid cancer is associated with high serum vitamin D level and polymorphism of vitamin D receptors.

Physiol Int 2020 Mar;107(1):120-133

5Cellular and Molecular Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Background: Thyroid cancer is the most common endocrine malignancy. Studies have observed an anti-cancer effect for vitamin D and found that polymorphisms of vitamin D receptors can influence the prevalence of various cancers. The present study investigated the serum level of vitamin D and FokI, BsmI and Tru9I polymorphisms of vitamin D receptors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1556/2060.2020.00011DOI Listing

Impact of multikinase inhibitor approval on survival and physician practice patterns in advanced or metastatic medullary thyroid carcinoma.

Surgery 2020 May 30. Epub 2020 May 30.

Department of Surgery, Weill Cornell Medical College, New York Presbyterian Hospital, NY.

Background: This study aimed to identify whether multikinase inhibitor approval for medullary thyroid carcinoma was associated with changes in systemic therapy administration or overall survival.

Methods: The National Cancer Database was queried for advanced medullary thyroid carcinoma patients. Clinicopathologic comparisons were performed between premultikinase inhibitor (2005-2010) and postmultikinase inhibitor (2011-2016) approval groups. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.surg.2020.03.021DOI Listing

First proof of association between autoimmune polyglandular syndrome and multiple endocrine neoplasia in humans.

Endocr J 2020 May 29. Epub 2020 May 29.

Department of Medicine (DIMED), Endocrinology Unit, Padua University, Padua, Italy.

Autoimmune Addison's disease (AAD) is a rare condition occurring either in isolation or associated with other autoimmune diseases as part of an autoimmune polyglandular syndrome (APS) type 1, 2 or 4. Multiple endocrine neoplasia (MEN) type 1, 2 or 4 is a hereditary autosomal dominant cancer syndrome. Medullary thyroid carcinoma and pheochromocytoma are neoplasms common to MEN-2a and MEN-2b. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1507/endocrj.EJ20-0099DOI Listing

Early thyroidectomy in multiple endocrine neoplasia: a four decade experience.

Endocr Relat Cancer 2020 May 1. Epub 2020 May 1.

R Gagel, Section of Endocrinology, MD Anderson Cancer Center, Houston, 77030-4009, United States.

Forty years ago, physicians caring for the J-kindred, a 100+ member family with multiple endocrine neoplasia type 2A (MEN2A), hypothesized that early thyroidectomy based on measurement of the biomarker calcitonin could cure patients at risk for development of medullary thyroid carcinoma (MTC). We re-evaluated 22 family members with proven RET proto-oncogene mutations (C634G) who underwent thyroidectomy and central lymphadenectomy between 1972-1994 based on stimulated calcitonin abnormalities. Current disease status was evaluated by serum calcitonin measurement and neck ultrasound in eighteen of the 22 prospectively screened patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-20-0108DOI Listing

Modulatory Role of Single Nucleotide Polymorphisms of Distinct Genetic Pathways on Clinical Behavior of Medullary Thyroid Carcinoma.

Asian Pac J Cancer Prev 2020 May 1;21(5):1289-1293. Epub 2020 May 1.

Sarin Lab, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre, Kharghar, Navi Mumbai, India.

Background: Role of RET proto-oncogene as predisposing gene for Medullary Thyroid Carcinoma is well established which provides the basis for clinical management of patients. However clinical behavior of MTC varies considerably among patients. Several studies have investigated whether SNPs in low penetrance genes could modulate the clinical behavior of MTC but with conflicting or inconclusive results. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.31557/APJCP.2020.21.5.1289DOI Listing

Cabozantinib as an emerging treatment for sarcoma.

Curr Opin Oncol 2020 May 20. Epub 2020 May 20.

GINECO and Medical Oncology Department, Centre Léon Bérard, Université Claude Bernard Lyon, Lyon, France.

Purpose Of Review: Sarcomas are a diverse group of rare solid tumors with limited treatment options for patients with advanced, inoperable disease. Cabozantinib is a tyrosine kinase inhibitor currently approved for advanced renal cell, hepatocellular, and medullary thyroid carcinoma. Cabozantinib has potent activity against a variety of kinases, including MET, vascular endothelial growth factor receptor, and AXL, that are associated with sarcoma growth and development. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/CCO.0000000000000644DOI Listing

A Proposed Grading Scheme for Medullary Thyroid Carcinoma Based on Proliferative Activity (Ki-67 and Mitotic Count) and Coagulative Necrosis.

Am J Surg Pathol 2020 May 22. Epub 2020 May 22.

Cancer Diagnosis and Pathology Group, Kolling Institute of Medical Research.

We investigated the prognostic value of a range of histologic parameters in medullary thyroid carcinoma (MTC) to design a grading system to predict overall survival. We assessed 76 patients with MTCs undergoing primary tumor resection for age, sex, tumor size, vascular space invasion, lymph node metastasis, multiple endocrine neoplasia type 2 (MEN2) status, mitotic count, Ki-67 proliferative index, spindled morphology, sheet-like growth pattern, coagulative necrosis, incipient necrosis, nuclear grade, multinucleation, prominent nucleoli, fibrosis, and amyloid deposition. In addition to the clinical features of age and the diagnosis of MEN2, the only histologic features that significantly predicted reduced overall survival were Ki-67 proliferative index, mitotic count, and the presence of coagulative necrosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000001505DOI Listing

Clinical and prognostic value of neutrophil-lymphocyte ratio for patients with thyroid cancer: A meta-analysis.

Medicine (Baltimore) 2020 May;99(20):e19686

College of Basic Medicine, Changchun University of Chinese Medicine, Changchun, Jilin Province, China.

Background: Although the malignant degree is relatively low and overall prognosis is excellent, some patients with thyroid cancer still experience metastasis during the follow-up, which leads to their possible death. Pretreatment neutrophil-to-lymphocyte ratio (NLR) has been recommended as a biomarker for the prediction of metastasis and prognosis in patients with cancers. However, its value in thyroid cancer remains inconclusive. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000019686DOI Listing

Renal calcitonin amyloidosis in a patient with disseminated medullary thyroid carcinoma.

Amyloid 2020 May 19:1-2. Epub 2020 May 19.

Renal Division, Department of Medicine, Peking University First Hospital; Institute of Nephrology, Peking University.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/13506129.2020.1738376DOI Listing

Variability in Medullary Thyroid Carcinoma in L790F Carriers: A Case Comparison Study of Index Patients.

Front Endocrinol (Lausanne) 2020 28;11:251. Epub 2020 Apr 28.

Center for Genomic Medicine, Copenhagen University Hospital, Copenhagen, Denmark.

Previous studies have suggested that the variability in age of onset and aggressiveness of medullary thyroid carcinoma (MTC) in patients with multiple endocrine neoplasia type 2A (MEN 2A) carrying the same arranged during ransfection () mutation may be caused by additional germline variants or somatic variants. This study was a retrospective case comparison study of all MEN 2A index patients ( = 2) with the L790F germline mutation in Denmark. Whole blood and MTC tissue were analyzed for germline variants and other somatic variants (>500), respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2020.00251DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7198720PMC

Clinical and ultrasonographic features of medullary thyroid microcarcinomas compared with papillary thyroid microcarcinomas: a retrospective analysis.

BMC Med Imaging 2020 May 14;20(1):49. Epub 2020 May 14.

Ultrasound Department, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, 197 Ruijin Er Rd, Shanghai, 200025, China.

Background: To identify the sonographic features that help to differentiate medullary thyroid microcarcinomas (MTMCs) from papillary thyroid microcarcinomas (PTMCs).

Methods: A total of 46 MTMCs in 41 patients and 136 PTMCs in 104 patients that were proven by surgery and pathology were included in the study. Patient age and nodule size were analyzed by independent sample t-tests, and sex, multiplicity and cervical lymph node metastases were analyzed by χ or Fisher's exact tests. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12880-020-00444-9DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7227110PMC

Chinese siblings with hereditary medullary thyroid carcinoma caused by RET mutation: implications for RET oncogene detection.

BMC Endocr Disord 2020 May 14;20(1):64. Epub 2020 May 14.

Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science & Technology, No.1095 Jie Fang Avenue, Wuhan, 430030, Hubei, China.

Background: Hereditary medullary thyroid carcinoma (MTC) is mainly caused by germline mutations in the RET proto-oncogene, which accounts for 20-30% of all MTC according to foreign studies. However, no English literatures have reported Chinese hereditary MTC. Here, we reported two Chinese brothers with MTC that caused by germline RET mutation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12902-020-0544-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222469PMC

First ever case report of co-occurrence of hobnail variant of papillary thyroid carcinoma and intrathyroid parathyroid adenoma in the same thyroid lobe.

Int J Surg Case Rep 2020 May 5;70:40-52. Epub 2020 May 5.

Department of General Surgery, Hamad General Hospital, Doha, Qatar.

Introduction: The hobnail variant of papillary thyroid cancer (PTC) is rare. Intrathyroid parathyroid adenoma (ITPA) is also rare. Co-ocurrence of PTC and ITPA in the same thyroid lobe is extremely rare. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijscr.2020.04.025DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7218145PMC

The prognostic value of lymph node ratio in Medullary thyroid carcinoma: A multi-center study.

Eur J Surg Oncol 2020 Apr 18. Epub 2020 Apr 18.

Department of Otolaryngology, Head and Neck Surgery, Rabin Medical Center - Beilinson Hospital, Petach Tikva, Israel; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. Electronic address:

Introduction: The lymph node ratio (LNR), which represents the proportion of metastatic lymph nodes resected, has been found to be a prognostic variable in several cancers, but data for Medullary thyroid carcinoma (MTC) are sparse. The aim of this study was to determine the value of the LNR in predicting outcome in patients with MTC.

Materials And Methods: A retrospective multicenter study design of 107 patients with MTC who underwent total thyroidectomy with neck dissection between 1984 and 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejso.2020.04.016DOI Listing
April 2020
3.009 Impact Factor

MEN2-related pheochromocytoma: current state of knowledge, specific characteristics in MEN2B, and perspectives.

Endocrine 2020 May 10. Epub 2020 May 10.

Department of Endocrinology, Aix-Marseille University, INSERM U1251, Endo-ERN Reference Center for Rare Genetic Tumor Syndromes, Assistance Publique-Hopitaux de Marseille, Marseille, France.

Multiple endocrine neoplasia type 2 (MEN2) is a rare hereditary syndrome due to mutations of the proto-oncogene REarranged during Transfection (RET), defined by the association of medullary thyroid carcinoma (MTC) in almost 100% cases, and pheochromocytoma in roughly 50% (primary hyperparathyroidism can be seen in 10-20% of patients with MEN2A). Early thyroidectomy and the efficacy of novel tyrosine kinase inhibitors modified the natural history of MTC, with possibilities of cure or long-term control. The second main compound, pheochromocytoma, is reported with a variable penetrance, from 10 to 80% cases, depending on the mutation of RET. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-020-02332-2DOI Listing

CALCITONIN REVISITED IN 2020.

Acta Endocrinol (Buchar) 2019 Oct-Dec;15(4):544-548

"Grigore T Popa" University of Medicine and Pharmacy, Faculty of Medicine - Endocrinology, Iasi, Romania.

Calcitonin (CT) is a polypeptidic hormone specifically secreted by the thyroid parafollicular cells (C cells) and tangentially involved in human phosphocalcic and bone metabolism. CT from other species (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4183/aeb.2019.544DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200115PMC

Primary hyperparathyroidism as first manifestation in MEN 2A: an international multicenter study.

Endocr Connect 2020 May 1. Epub 2020 May 1.

J Mathiesen, Department of ORL Head and Neck Surgery and Audiology, Odense University Hospital, Odense, Denmark.

Objective: Multiple endocrine neoplasia type 2A (MEN 2A) is a rare syndrome caused by RET germline mutations, and have been associated with primary hyperparathyroidism (PHPT) in up to 30% of cases. Recommendations on RET screening in patients with apparently sporadic PHPT are unclear. We aimed to estimate the prevalence of cases presenting with PHPT as first manifestation among MEN 2A index cases and to characterize the former cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/EC-20-0163DOI Listing

Signification of forkhead box A1 (FOXA1) expression in thyroid cancers.

J Egypt Natl Canc Inst 2019 Dec 30;31(1):11. Epub 2019 Dec 30.

Research Unit UR14ES17, Medicine Faculty, University of Sousse, Sousse, Tunisia.

Background: Forkhead box A1 (FOXA1) plays an important role in several tumors. This study investigated the potential role of FOXA1 expression in thyroid tumors. We conducted a retrospective study of 110 thyroid lesions and tumors diagnosed during 1995-2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s43046-019-0011-2DOI Listing
December 2019

Efficacy and safety of concomitant 177Lu-DOTATATE and low-dose capecitabine in advanced medullary thyroid carcinoma: a single-centre experience.

Nucl Med Commun 2020 May 1. Epub 2020 May 1.

Otolaryngology (Head and Neck Surgery), Post Graduate Institute of Medical Education and Research (PGIMER), Chandigarh, India.

Aims: Peptide receptor radionuclide therapy (PRRT) has been shown to be useful in inoperable/metastatic medullary thyroid carcinoma (MTC). However, the role of concomitant PRRT and low-dose capecitabine therapy has not yet been studied in these patients. This study was conducted to evaluate the efficacy and safety of this combination approach in advanced MTC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MNM.0000000000001205DOI Listing

[Modern thyroid surgery - the surgeon's endocrine-surgical understanding and his responsibility for the extent of surgery and complication rate].

Wien Med Wochenschr 2020 Apr 27. Epub 2020 Apr 27.

Chirurgie, Sanatorium Kettenbrücke der Barmherzigen Schwestern, Sennstraße 1, 6020, Innsbruck, Österreich.

High quality thyroid surgery implies a surgeon with an endocrine-surgical understanding aiming at best possible outcome. This includes an appropriate extent of the resection and a low rate of complications. It is important that the surgeon is involved at an early stage being part of the decision process for or against partial or total thyroidectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10354-020-00750-5DOI Listing

Medullary Thyroid Carcinoma Surveillance Study: a Case-Series Registry.

Thyroid 2020 Apr 22. Epub 2020 Apr 22.

United BioSource Corp, 43684, Blue Bell, Pennsylvania, United States;

Not Applicable. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2019.0591DOI Listing

Grading of medullary thyroid carcinoma on the basis of tumor necrosis and high mitotic rate is an independent predictor of poor outcome.

Mod Pathol 2020 Apr 20. Epub 2020 Apr 20.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Medullary thyroid carcinoma (MTC) is a rare nonfollicular cell-derived tumor. A robust grading system may help better stratify patients at risk for recurrence and death from disease. In total, 144 MTC between 1988 and 2018 were subjected to a detailed histopathologic evaluation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-020-0532-1DOI Listing

What Is the Extent of Neck Dissection in Medullary Thyroid Carcinoma?

Laryngoscope 2020 Apr 20. Epub 2020 Apr 20.

Department of Otolaryngology/Head Neck Surgery, Louisiana State University Health Sciences Center (LSU Health), Shreveport, Louisiana, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/lary.28686DOI Listing

Ceruloplasmin Status in Medullary Thyroid Carcinoma.

Iran J Public Health 2020 Jan;49(1):209-210

Cellular and Molecular Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152641PMC
January 2020
0.576 Impact Factor

Update on the Treatment of Medullary Thyroid Carcinoma in Patients with Multiple Endocrine Neoplasia Type 2.

Horm Metab Res 2020 Apr 16. Epub 2020 Apr 16.

Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA.

Medullary Thyroid Carcinoma (MTC) is a rare neuroendocrine cancer that accounts for 1-2% of thyroid cancers in the United States (U.S.). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-1145-8479DOI Listing

Novel Findings on SPECT-CT Tc-99 Sestamibi Imaging for Primary Hyperparathyroidism.

J Surg Res 2020 Apr 11;252:216-221. Epub 2020 Apr 11.

Division of Endocrine Surgery, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania. Electronic address:

Background: The addition of SPECT-CT to Tc-99 sestamibi has become a valuable tool for parathyroid localization in primary hyperparathyroidism (PHP). However, the enhanced sensitivity of this test can lead to unexpected and significant findings. We sought to identify the frequency and types of nonparathyroid detections by SPECT-CT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jss.2020.03.014DOI Listing

Identifying novel oncogenic mutations and characterising their sensitivity to RET-specific inhibitors.

J Med Genet 2020 Apr 13. Epub 2020 Apr 13.

Internal Medicine-Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China

Background: Rearranged during transfection () is a well-known proto-oncogene. Multiple oncogenic alterations have been identified, including fusions and mutations. Although fusions have been reported in multiple cancers, mutations were mainly found in multiple endocrine neoplasia type 2 and medullary thyroid carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jmedgenet-2019-106546DOI Listing

Thyroid cancer histological subtypes based on tumor size: National perspective.

Head Neck 2020 Apr 10. Epub 2020 Apr 10.

Endocrine and Oncological Surgery Division, Department of Surgery, Tulane University School of Medicine, New Orleans, Louisiana, USA.

Background: Thyroid tumor size is an important prognostic factor. The aim of this study is to examine the histological subtypes and management of thyroid cancer based on tumor size (≤4 cm vs >4 cm).

Methods: Retrospective cohort study utilizing the National Cancer Database, 2004-2014. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/hed.26159DOI Listing

Calcitonin levels by ECLIA correlate well with RIA values in higher range but are affected by sex, TgAb, and renal function in lower range.

Endocr J 2020 Apr 8. Epub 2020 Apr 8.

Department of Laboratory Medicine, School of Medicine, Fukushima Medical University, Fukushima 960-1295, Japan.

Calcitonin (CT) is a marker for both initial diagnosis and monitoring of patients with residual or recurrent medullary thyroid carcinoma (MTC). In Japan, serum CT had been measured by radioimmunoassay (RIA) until recently. Electrochemiluminescence immunoassay (ECLIA) became commercially available in 2014, and this technique is now the only method used to examine CT concentration. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1507/endocrj.EJ19-0610DOI Listing

The revised clinical practice guidelines on the management of thyroid tumors by the Japan Associations of Endocrine Surgeons: Core questions and recommendations for treatments of thyroid cancer.

Endocr J 2020 Apr 9. Epub 2020 Apr 9.

Department of Breast and Endocrine Surgery, Tokyo Women's Medical University, Tokyo 162-8666, Japan.

The Japan Associations of Endocrine Surgeons has developed the revised version of the Clinical Practice Guidelines for Thyroid Tumors. This article describes the guidelines translated into English for the 35 clinical questions relevant to the therapeutic management of thyroid cancers. The objective of the guidelines is to improve health-related outcomes in patients with thyroid tumors by enabling users to make their practice evidence-based and by minimizing any variations in clinical practice due to gaps in evidential knowledge among physicians. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1507/endocrj.EJ20-0025DOI Listing

High-specific-activity iodine 131 metaiodobenzylguanidine for the treatment of metastatic pheochromocytoma or paraganglioma: a novel therapy for an orphan disease.

Curr Opin Endocrinol Diabetes Obes 2020 Jun;27(3):162-169

Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Purpose Of Review: Pheochromocytomas and paragangliomas represent less than 1% of all endocrine tumors. Approximately 15-20% of these tumors are malignant. The definition of malignancy relies on the presence of metastasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MED.0000000000000544DOI Listing

Case of medullary thyroid carcinoma with desmoid-type fibromatosis.

Pathol Int 2020 Jun 5;70(6):364-369. Epub 2020 Apr 5.

Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.

A 36-year-old man was admitted to hospital for a right thyroid nodule incidentally discovered on a chest computed tomography scan for a rib fracture. He had no history of radiation to the head and neck, no known family history of endocrine disease, and no medical or surgical history. A 17 × 10 mm, well-demarcated, multinodular, whitish nodule with neither necrosis nor hemorrhage was found in the right thyroid. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pin.12926DOI Listing

Medullary thyroid cancer: epidemiological pattern and factors contributing to recurrence and metastasis.

Ann R Coll Surg Engl 2020 Apr 1:1-5. Epub 2020 Apr 1.

Mansoura University, Egypt.

Introduction: Medullary thyroid carcinoma (MTC) is a neuroendocrine thyroid carcinoma with parafollicular C cell differentiation. It can occur in either sporadic or hereditary form. Surgery is still the only curative treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1308/rcsann.2020.0056DOI Listing

A BRAF V600E Mutation in RET-Negative Medullary Thyroid Cancer.

Case Rep Endocrinol 2020 10;2020:7641940. Epub 2020 Mar 10.

Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Houston Methodist Hospital, Houston, TX, USA.

We report the case of a woman with a sporadic medullary thyroid carcinoma. Genomic analysis found that her tumor did not contain any common mutations but did harbor a V600E mutation. Only one other well-confirmed example of the BRAF V600E mutation has been reported in an MTC patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/7641940DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7085839PMC

Polymorphisms Within the Proto-Oncogene and Risk of Sporadic Medullary Thyroid Carcinoma.

Thyroid 2020 May 5. Epub 2020 May 5.

Endocrine Unit, Department of Clinical and Experimental Medicine, University Hospital of Cisanello, Pisa, Italy.

Sporadic medullary thyroid carcinoma (sMTC) is an uncommon neoplasia arising from the calcitonin-producing parafollicular cells of the thyroid. Previous studies evaluated whether single nucleotide polymorphisms (SNPs) within (a pivotal proto-oncogene for this disease) are associated with the risk for developing sMTC, but the results are inconclusive. In this work, we evaluated the association of -SNPs c. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2019.0352DOI Listing

Effect of Lenvatinib on a Patient with Medullary Thyroid Carcinoma Liver Metastasis Caused by Multiple Endocrine Neoplasia Type 2A.

Tokai J Exp Clin Med 2020 Apr 20;45(1):18-23. Epub 2020 Apr 20.

Department of Internal Medicine, Kanagawa Dental School, Inaoka-cho 82, Yokosuka, Kanagawa 238-8580, Japan.

A 61-year-old female was diagnosed with multiple endocrine neoplasia type 2A (MEN2A), caused by a heterozygous point mutation in the RET gene (TGC to TAC at codon 634) resulting in the substitution of cytosine with leucine (C634Y). The patient had pheochromocytoma (PCC) in the left adrenal gland and medullary thyroid carcinoma (MTC) with liver metastasis. Primary hyperparathyroidism (PHP) was not evident. Read More

View Article

Download full-text PDF

Source

Multiple Auer Rods in Fine-Needle Aspiration Smears of Medullary Thyroid Carcinoma: An Unusual Finding.

Int Med Case Rep J 2020 10;13:85-88. Epub 2020 Mar 10.

Department of Pathology, Shiraz University of Medical Sciences, Shiraz, Iran.

Background: Medullary thyroid carcinoma (MTC) is a rare tumor. Fine-needle aspiration (FNA) cytology is a popular method for the preoperative diagnosis of MTC.

Case Report: A 45-year-old man was referred to our center for a palpable thyroid nodule. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/IMCRJ.S244905DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7071880PMC

Insulinoma-associated protein 1 (INSM-1) expression in medullary thyroid carcinoma FNA: a multi-institutional study.

J Am Soc Cytopathol 2020 May - Jun;9(3):185-190. Epub 2020 Feb 21.

Department of Pathology, Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland; Department of Pathology, Fimlab Laboratories, Tampere, Finland.

Introduction: Insulinoma-associated protein 1 (INSM-1) is expressed in both normal tissues and neoplasms with neuroendocrine differentiation such as small cell lung carcinoma and pancreatic neuroendocrine tumors. The aim of this study was to evaluate the INSM-1 expression in medullary thyroid carcinoma (MTC) in the aspirated material and its preoperative diagnostic value.

Materials And Methods: MTC cases with available cytological material from 5 institutions were retrospectively identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jasc.2020.01.005DOI Listing
February 2020

Germline variants underlie a subset of paediatric osteosarcoma.

J Med Genet 2020 Mar 16. Epub 2020 Mar 16.

Institute for Medical Genetics and Pathology, University Hospital Basel, Basel, Switzerland.

Background: Although considerable effort has been put into decoding of the osteosarcoma genome, very little is known about germline mutations that underlie this primary malignant tumour of bone.

Methods And Results: We followed here a coincidental finding in a multiple endocrine neoplasia family in which a 32-year-old patient carrying a germline pathogenic mutation developed an osteosarcoma 2 years after the resection of a medullary thyroid carcinoma. Sequencing analysis of additional 336 patients with osteosarcoma led to the identification of germline activating mutations in the proto-oncogene in three cases and somatic amplifications of the gene locus in five matched tumours (4%, n=5/124 tumours). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jmedgenet-2019-106734DOI Listing

Calcitonin testing for detection of medullary thyroid cancer in people with thyroid nodules.

Cochrane Database Syst Rev 2020 03 16;3:CD010159. Epub 2020 Mar 16.

University of Groningen, University Medical Center Groningen, Department of Endocrinology, Hanzeplein 1, Groningen, Netherlands, 9713 GZ.

Background: Thyroid nodules are very common in general medical practice, but rarely turn out to be a medullary thyroid carcinoma (MTC). Calcitonin is a sensitive tumour marker for the detection of MTC (basal calcitonin). Sometimes a stimulation test is used to improve specificity (stimulated calcitonin). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD010159.pub2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7075519PMC

Combining serum calcitonin, carcinoembryonic antigen, and neuron-specific enolase to predict lateral lymph node metastasis in medullary thyroid carcinoma.

J Clin Lab Anal 2020 Mar 6:e23278. Epub 2020 Mar 6.

Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.

Background: This study aimed to investigate the clinical application of combined detection of serum calcitonin (Ctn), carcinoembryonic antigen (CEA), and neuron-specific enolase (NSE) in predicting lateral lymph node metastasis (LLNM) in medullary thyroid carcinoma (MTC).

Methods: Seventy-four consecutive patients with MTC were enrolled. The relationship between serum Ctn, CEA, and NSE and LLNM was retrospectively analyzed by univariate analysis and logistic regression analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/jcla.23278DOI Listing

Paraganglioma-like medullary thyroid carcinoma: A case report and literature review.

Diagn Cytopathol 2020 Jun 3;48(6):559-563. Epub 2020 Mar 3.

Department of Pathology, Robert J. Tomsich Pathology and Laboratory Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.

Medullary thyroid carcinoma (MTC) accounts for 3%-5% of all thyroid malignancies. Most MTC can be diagnosed by their typical cytologic and histologic morphology and immunohistochemical features. However, some rare variants of MTC may pose diagnostic difficulties on both cytology and histology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/dc.24403DOI Listing

The overall risk of malignancies is not increased in patients with Hirschsprung disease.

Pediatr Surg Int 2020 Apr 26;36(4):471-475. Epub 2020 Feb 26.

Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.

Purpose: Hirschsprung disease (HSCR) has previously been associated with increased risk of medullary thyroid cancer. The aim of this study was to assess the overall risk of malignancies in patients with Hirschsprung disease in a population-based cohort.

Methods: This was a nationwide, population-based cohort study. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00383-020-04631-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7069915PMC

Thyroid Cancer Incidence Trends in the United States: Association with Changes in Professional Guideline Recommendations.

Thyroid 2020 Apr 3. Epub 2020 Apr 3.

Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.

Overdiagnosis is the leading factor contributing to the rapid increase in thyroid cancer incidence of the last decades. During this period, however, thyroid cancer incidence has not been increasing at a constant pace. We hypothesized that changes in the slope of the incidence trends curve, called joinpoints, could be associated with changes in clinical practice guideline recommendations. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2019.0415DOI Listing

Medullary thyroid carcinoma of unknown primary origin with synchronous finding of papillary thyroid carcinoma.

Endokrynol Pol 2020 25;71(2):200-201. Epub 2020 Feb 25.

Department of General, Endocrine, and Transplant Surgery, Medical University of Gdańsk, Gdańsk, Poland.

Not required for Clinical Vignette. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.5603/EP.a2020.0003DOI Listing
February 2020

Bone Metastases in Medullary Thyroid Carcinoma: High Morbidity and Poor Prognosis Associated With Osteolytic Morphology.

J Clin Endocrinol Metab 2020 Jun;105(6)

University Hospital, University of Würzburg, Department of Internal Medicine I, Division of Endocrinology/Diabetology, Würzburg, Germany.

Context: The clinical relevance of bone metastases (BM) in advanced medullary thyroid carcinoma (MTC) is poorly described.

Objective: The objectives of this work are to describe the prevalence of BM, frequency of skeletal related events (SREs), and impact of BM morphology and SREs on prognosis, and to assess the role of antiresorptive treatment (ART).

Design: A retrospective cohort study was conducted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1210/clinem/dgaa077DOI Listing

Commentary on the study of Li J et al: The KWAK TI-RADS and 2015 ATA guidelines for medullary thyroid carcinoma, combined with cell block-assisted ultrasound-guided thyroid fine-needle aspiration.

Clin Endocrinol (Oxf) 2020 May 17;92(5):407-408. Epub 2020 Feb 17.

Department of Endocrine Surgery, Third Chair of General Surgery, Jagiellonian University, Medical College, Kraków, Poland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/cen.14165DOI Listing

Clinical and Translational Challenges in Thyroid Cancers

Curr Med Chem 2020 02 14. Epub 2020 Feb 14.

Medical Oncology Department. Gastrointestinal and Endocrine Tumor Unit Vall d´Hebron University Hospital Vall Hebron Institute of Oncology (VHIO) Pg Vall d´Hebron 119-129 08035 Barcelona . Spain.

Thyroid cancer is the most common endocrine malignancy and it accounts for 1% of all newly diagnosed tumors. Approximately 10% of patients with differentiated thyroid carcinomas (DTC) and 30% with medullary thyroid carcinoma (MTC) will not be cured with locoregional treatment and will develop metastatic disease. In addition, one of the most aggressive solid tumors can arise from the thyroid gland, the anaplastic thyroid carcinoma, with a median overall survival of less than 6 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2174/0929867327666200214125712DOI Listing
February 2020

Comparison of 5 Different PET Radiopharmaceuticals for the Detection of Recurrent Medullary Thyroid Carcinoma: A Network Meta-analysis.

Clin Nucl Med 2020 May;45(5):341-348

Department of Nuclear Medicine, Pusan National University Yangsan Hospital.

Purpose: The aim of this study is to investigate and compare the performance of different PET radiopharmaceuticals for the detection of recurrent medullary thyroid carcinoma (MTC) by performing a network meta-analysis (NMA) using direct comparison studies with 2 or more PET radiopharmaceuticals.

Methods: PubMed and EMBASE were searched for the studies evaluating the performance of PET or PET/CT for the detection of recurrent MTC. The NMA was performed for different PET radiopharmaceuticals in both patient- and lesion-based analyses and with a threshold of serum calcitonin or carcinoembryonic antigen (CEA) levels and calcitonin doubling time. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002940DOI Listing